Opinion
Video
Additional Key Takeaways of ASCO 2024 Data in mCR
Author(s):
The panel of leading oncologists summarize crucial updates and key insights on colorectal cancer from the ASCO 2024 conference.
EP: 1.Overview of Molecular Testing and Barriers in mCRC
EP: 2.Clinical Considerations for 2L Treatment Sequencing in mCRC
EP: 3.Novel Combination Regimens for 2L mCRC: Insights from ASCO 202
EP: 4.Exploring Toxicities for Second Line Treatments in mCRC
EP: 5.Existing Challenges for Patients Receiving 3L+ Therapies in mCRC
EP: 6.Factors Driving 3L Therapeutic Selection for mCRC
EP: 7.Exploring Data Outcomes From the SUNLIGHT Trial
EP: 8.Fruquintinib for mCRC: Data from the FRESCO & FRESCO-2 Studies
EP: 9.Examining the Evolving 3L Treatment Landscape for mCRC
Now Viewing
EP: 10.Additional Key Takeaways of ASCO 2024 Data in mCR
EP: 11.Future Outlooks in the Treatment of Metastatic Colorectal Cancer
- Can each of you share any noteworthy key takeaways or additional data updates on mCRC treatment discussed at ASCO 2024? (if time permits)
Related Videos
Related Content
